Skip to main
DYN

Dyne Therapeutics (DYN) Stock Forecast & Price Target

Dyne Therapeutics (DYN) Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 46%
Buy 38%
Hold 15%
Sell 0%
Strong Sell 0%

Bulls say

Dyne Therapeutics is a pre-commercial stage company with a promising pipeline of targeted therapeutics for neuromuscular diseases, utilizing their innovative FORCE platform. However, the company faces significant competition and will likely need to raise debt or equity funds in the future. The success of their clinical trials, potential regulatory challenges, and ultimate market penetration will determine the company's future financial performance. Despite these risks, the potential for a positive read-through from competitor Avidity's DM1 Phase III readout in 2026 could lead to significant upside potential for Dyne's stock.

Bears say

Dyne Therapeutics is a pre-commercial stage company that faces significant competition in the gene therapy/oligonucleotide medicines space. Its key intellectual property could fail to protect its products and it may face legal expenses from potential IP infringement suits. The company's development pipeline has products that could be protected by market exclusivity from orphan drug designations, but there is no assurance that this will ultimately provide protection against competitors. Dyne also faces additional clinical and regulatory risks, and its future fundraising and stock prices may be impacted by the progress of its research and clinical programs.

Dyne Therapeutics (DYN) has been analyzed by 13 analysts, with a consensus rating of Buy. 46% of analysts recommend a Strong Buy, 38% recommend Buy, 15% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dyne Therapeutics (DYN) Forecast

Analysts have given Dyne Therapeutics (DYN) a Buy based on their latest research and market trends.

According to 13 analysts, Dyne Therapeutics (DYN) has a Buy consensus rating as of May 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35.92, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35.92, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dyne Therapeutics (DYN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.